The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a pilot, randomized, single-center, parallel group, open-label controlled study to
evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus
Standard of Care (SOC) versus SOC alone in hospitalized cancer patients with COVID-19. King
Hussein Cancer Center (KHCC) is the study sponsor, and the study will be conducted at KHCC
COVID-19 wards.
Approximately 28 cancer patients, ≥18 years of age with a confirmed SARS-CoV-2 infection,
will be enrolled and randomized 1:1 to the treatment and control arms where they will receive
ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm
where treatment will follow KHCC SOC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
King Hussein Cancer Center
Collaborators:
ACDIMA Biocenter ACDIMA Center for Bioequivalence and Pharmaceutical Studies (ACDIMA BioCenter) Amman Pharmaceutical Industries (API) Sana Pharmaceutical Industry